Neopharm Co (KOSDAQ:92730) cover image
14 Reads (3 mins read)

What's the future for the Neopharm Co (KOSDAQ:92730) share price?

22nd May by Ben Hobson

Given the present disruption and volatility in the stock market, it is more important than ever to identify high quality stocks for your portfolio. That means knowing how to find highly profitable companies that are able to fend off competitive threats over the long term.

These sorts of stocks are different because they've got what billionaire investor Warren Buffett calls economic moats

Defensive moats let companies compound returns at above-average rates over long periods. They can be an investment goldmine. And while these stocks can be hard to find, there are signs that Neopharm Co (KOSDAQ:92730) might be one of them.      

Before we get started on why this looks like a high quality business, here are some of the main ways that a company can build a strong moat around itself:   

  • Intangible Assets - Such as brands that customers love, valuable patents or regulatory approvals
  • Switching Costs - It might be too costly, complicated or unnecessary for customers to look elsewhere
  • Network Effects - When customers become part of a product it creates tremendously powerful businesses
  • Cost Advantages - Superior processes and unique locations and assets make it hard for others to compete
  • Great Scale - Large infrastructure and distribution networks are powerful barriers to entry in many industries

So the question is whether Neopharm Co is showing the signs of having a profitable competitive edge - and the way to find that out is to look at its financials...

GET MORE DATA-DRIVEN INSIGHTS INTO KOSDAQ:92730 »

Has Neopharm Co (KOSDAQ:92730) got a moat?

Some of the biggest indicators of a moat involve persistent strong margins and high levels of cash generation – cash being very important given the uncertainty about the economy. Here are a few ways of gauging these characteristics - and how Neopharm Co compares:

  1. High rates of Free Cash Flow - the measure of a thriving company.
    - A high ratio of free cash flow to sales can be a very positive sign. For Neopharm Co, the figure is an impressive 20.9%. 
  2. High Return on Capital Employed - the measure of a company growing efficiently and profitably.
    - A 5-year average ROCE of more than 12 percent is a pointer to strong efficiency. For Neopharm Co, the figure is an eye-catching 24.1%.
  3. High Return on Equity (compared to peers) - the measure of a company making good profits from its assets.
    - Neopharm Co has a 5-year average ROE of 22.3%.
  4. High Operating Margins (compared to peers) - the measure of a company with pricing power
    - Neopharm Co has a 5-year average operating margin of 23.5%.

Next steps

Some of the best quality stocks in the market have defensible models that can deliver high levels of shareholder returns over the long term. By analysing some key medium-term profitability and efficiency metrics, it's possible to start tracking them down. On this basis, it certainly appears that Neopharm Co has some of the financial traits of an economic moat.

To find out more you might want to take a look at the KOSDAQ:92730 StockReport from the award-winning research platform, Stockopedia. StockReports contain a goldmine of information in a single page and can help to inform your investment decisions.

To find more stocks like Neopharm Co, you'll need to equip yourself with professional-grade data and screening tools. This kind of information has traditionally been closely guarded by professional fund managers. But our team of financial analysts have carefully constructed this screen - Stockopedia’s Moats of the FTSE 350 - which gives you everything you need. So why not come and take a look?

Share this article
As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.
Share Price
KRW38500
Change Today
0.13%
Neopharm Co ( )

Stockopedia is here to help individual investors beat the markets by being the very best in stock analysis, research & community. Take a 30 day free trial of our extensive multi-award winning service and find out why more than ten thousand global investors can't live without it.

© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.